How to treat of a first episode of ascites?;Comment traiter une première poussée d'ascite?

Gastroenterologie Clinique et Biologique

Volumn 28, Issue SPEC. ISS. 2, 2004, Pages

  Pariente, Alexandre ^a  

^a CENTRE HOSPITALIER DE PAU   (France)

Author keywords

[No Author keywords available]

Indexed keywords

DIURETIC AGENT; FUROSEMIDE; SPIRONOLACTONE;

ASCITES; BACTERIAL PERITONITIS; CHYLOUS ASCITES; CONFERENCE PAPER; DIET RESTRICTION; DIURETIC THERAPY; HERNIA; HOSPITALIZATION; HUMAN; LIVER CIRRHOSIS; PARACENTESIS; PORTOCAVAL SHUNT; PORTOSYSTEMIC ANASTOMOSIS; TREATMENT INDICATION;

ASCITES; DIET, SODIUM-RESTRICTED; DIURETICS; HUMANS; LIVER CIRRHOSIS; PROGNOSIS; PUNCTURES; SODIUM;

EID: 2442527915     PISSN: 03998320     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Conference Paper

References (98)

1. Conn HO. The paracentesis pendulum. Hepatology 1985;5:521-2.
2. Runyon BA. Historical aspects of treatment of patients with cirrhosis and ascites. Seminars Liver Dis 1997;17:163-73.
3. Runyon BA. Management of adult patients with ascites caused by cirrhosis. (AASLD practice guidelines). Hepatology 1998;27:264-72.
4. Salerno F, Angeli P, Bernardi M, Laffi G, Riggio O, Salvagnini M. Clinical practice guidelines for the management of cirrhotic patients with ascites. Committee on Ascites of the Italian Association for the Study of the Liver. Ital J Gastroenterol Hepatol 1999;31:626-34.
5. Diagnostic et traitement de l'ascite. Recommandations pour la pratique clinique (Groupe de travail RCP ascite). Rev Med Suisse Romande 2000;120:827-38.
6. Moreau R. Traitement de l'ascite dans la cirrhose. Presse Med 2001;30:695-702.
7. Gentilini P, Vizzutti F, Gentilini A, Zipoli M, Foschi M, Romanelli RG. Update on ascites and hepatorenal syndrome. Dig Liver Dis 2002;34:592-605.
8. Arroyo V, Colmenero J. Ascites and hepatorenal syndrome in cirrhosis: pathophysiological basis of therapy and current management. J Hepatol 2003;38:S69-S89.
9. Moore KP, Wong F, Gines P, Bernardi M, Ochs A, Salerno F, et al. The management of ascites in cirrhosis: report on the consensus conference of the international ascites club. Hepatology 2003;38:258-66.
10. Schrier RW, Arroyo V, Bernardi M, Epstein M, Henriksen JH, Rodès J. Peripheral vasodilation hypothesis: a proposal for the initiation of renal sodium and water retention in cirrhosis. Hepatology 1988;8:1151-7.
11. Blendis L, Wong F. Intravenous albumin with diuretics: protean lessons to be learnt. J Hepatol 1999;30:727-30.
12. Gines P, Quintero E, Arroyo V, Teres J, Brugera, Rimola A, et al. Compensated cirrhosis: natural history and prognostic factors. Hepatology 1987;7:122-8.
13. Kamath PS, Wiesner RH, Malinchoc M, Kremers W, Therneau TM, Kosberg CL, et al. A model to predict survival in patients with end-stage liver disease. Hepatology 2001;33:464-70.
14. Arroyo V, Bosch J, Gaya J, Kravetz D, Estrada L, Rivera F, et al. Plasma renin activity and urinary sodium excretion as prognostic indicators in non-azotemic cirrhosis with ascites. Ann Intern Med 1981;94:198-201.
15. Llach J, Ginès P, Arroyo V, Rimola V, Tito L, Baldalamenti S, et al. Prognostic value of arterial pressure, endogenous vasoactive systems, and renal function in cirrhotic patients admitted to the hospital for the treatment of ascites. Gastroenterology 1988;94:482-7.
16. Vorobioff J, Groszmann RL, Picabea E, Gamen M, Villavicencio R, Bordato J, et al. Prognostic value of hepatic venous pressure gradient measurement in alcoholic cirrhosis: prospective study. Gastroenterology 1996;111:701-9.
17. Pessione F, Ramond MJ, Peters L, Pham BN, Batel P, Rueff B, et al. Five-year survival predictive factors in patients with excessive alcohol intake and .. Effect of alcoholic hepatitis, smoking and abstinence. Liver International 2003;23:45-53.
18. Mathurin P, Mendenhall CL, Carithers RL Jr, Ramond MJ, Maddrey WC, Garstide P, et al. Corticosteroids improve short-term survival in patients with severe alcoholic hepatitis (AH): individual data analysis of the last three randomized placebo controlled double blind trials of corticosteroids in severe AH. J Hepatol 2002;36:408-17.
19. Yoshida H, Arakawa Y, Sata M, Nishigushi S, Yano M, Fujiyama S, et al. Interferon therapy prolonged life expectancy among chronic hepatitis C patients. Gastroenterology 2002;123:483-91.
20. Poli G, Pozzi M, Redaelli A, Roffi L, Minola E, Redaelli E, et al. Decreased ascites occurrence in interferon (IFN) treated HCV cirrhosis: results of a survey of a large cohort of interferon treated and untreated patients (abstract). J Hepatol 2002;36(S1):244.
21. Imazeki F, Yokosuka O, Fukai K, Saisho H. Favorable prognostic of chronic hepatitis C after interferon therapy by long term cohort study. Hepatology 2003;38:493-502.
22. Villeneuve JP, Condreay LD, Willems B, Pomier-Layrargues G, Fenyves D, Bilodeau M, et al. Lamivudine treatment for decolmpensated cirrhosis resulting from chronic hepatitis B. Hepatology 2000;31:207-10.
23. Janssen HL, Garcia-Pagan JC, Elias E, Mentha G, Hadengue A, Valla DC. Budd-Chiari syndrome: a review by an expert panel. J Hepatol 2003;38:364-71.
24. Poupon RE, Poupon R, Balkau B. Ursodiol for the long-term treatment of primary biliary cirrhosis. The UDCA-PBC Study Group. N Engl J Med 1994;330:1342-7.
25. Pariente A. Hépatites auto-immunes: prise en charge thérapeutique. Gastroenterol Clin Biol 2003;27 (suppl 5):B13-19.
26. Niederau C, Fischer R, Purschel A, Stremmel W, Haussinger D, Strohmeyer G. Long-term survival in patients with hereditary hemochromatosis. Gastroenterology 1996;110:1107-19.
27. Roberts EA, Schilsky ML. A practice guideline on Wilson disease. Hepatology 2003;37:1475-92.
28. Hammel P, Couvelard A, O'Toole D, Ratouis A, Sauvanet A, Flejou JF, et al. Regression of liver fibrosis after biliary drainage in patients with chronic pancreatitis and stenosis of the common bile duct. N Engl J Med 2001;344:418-23.
29. Jiménez W, Martinez-Pardo A, Arroyo V, Bruix J, Rimola A, Gaya J, et al. Temporal relationship between hyperaldosteronism, sodium retention and ascites formation in rats with experimental cirrhosis. Hepatology 1985;5:245-50.
30. Abecasis R, Kravetz D, Fassio E, Ameigeiras B, Garcia D, Isla R, et al. Nadolol plus spironolactone in the prophylaxis of first variceal bleed in nonascitic cirrhotic patients: a preliminary study. Hepatology 2003;37:359-65.
31. Sansoè G, Ferrari A, Baraldi E, Castellana CN, De Santis MC, Manenti F. Renal distal tubular handling of sodium in central fluid volume homeostasis in preascitic cirrhosis. Gut 1999;45:750-5.
32. Brunin JP, Bories P, Ampelas M, Mimran A, Michel H. Pseudohyperaldostéronisme induit par le pastis sans alcool. Gastroenterol Clin Biol 1984;8:711-4.
33. Hasegawa M, Yamada S, Hirayama C. Fasting plasma caffeine level in cirrhotic patients: relation to plasma levels of catecholamines and rennin activity. Hepatology 1989;6:973-7.
34. Calès P. Propranolol in the prevention of ascites. Lancet 1991;338:509-10.
35. Pérez-Ayuso RM, Pique JM, Bosch J, Panes J, Gonzalez A, Perez R, et al. Propranolol in prevention of recurrent bleeding from severe portal hypertensive gastropathy in cirrhosis. Lancet 1991;337:1431-4.
36. Castells A, Salo J, Planas R, Quer JC, Gines A, Boix J, et al. Impact of shunt surgery for variceal bleeding in the natural history of ascites in cirrhosis: a retrospective study. Hepatology 1994;20:584-91.
37. Rodès J, Arroyo V. Effet des maladies hépatiques sur le système urogénital. In: Hépatologie clinique. Benhamou JP, Bircher J, McIntyre N, Rizzetto M, Rodès J, éditeurs. Flammarion Médecine-Sciences, Paris 2002, pp 1831-6.
38. Ma Z, Lee SS. Cirrhotic cardiomyopathy: getting to the heart of the matter. Hepatology 1996;24:451-9.
39. Pare P, Talbot J, Hoefs JC. Serum-ascites albumin gradient: a physiologic approach to the differential diagnosis of ascites. Gastroenterology 1983;85:240-4.
40. Runyon BA, Montano AA, Akriviadis EA, Antillon MR, Irving MA, McHutchinson JG. The serum-ascites albumin gradient is superior to the exudate-transudate concept in the differential diagnosis of ascites. Ann Intern Med 1992;117:215-20.
41. Kammerer J, Dupeyron C, Vuillemin N, Leluan G, Fouet P. Importance de l'examen cytologique et bactériologique de l'ascite des malades cirrhotiques pour le diagnostic de péritonite bactérienne. A propos de 610 prélèvements chez 156 malades. Med Chir Dig 1982;11:243-51.
42. Rimola A, Garcia-Tsao G, Navasa M, Piddock LJ, Planas R, Bernard B, et al. Diagnosis, treatment and prophylaxis of spontaneous bacterial peritonitis: a consensus document. J Hepatol 2000;32:142-53.
43. Bernardi M, Di Marco C, Trevisani F, Fornale R, Andreone P, Cursaro C, et al. Renal sodium retention during upright posture in preascitic cirrhosis. Gastroenterology 1993;105:188-93.
44. Bernardi M, Santini C, Trevisani F, Baraldini M, Ligabue A, Gasbarrini G. Renal function impairment induced by change in posture in patients with cirrhosis and ascites. Gut 1985;26:629-35.
45. Ring-Larsen H, Henriksen JH, Wilken C, Clausen J, Pals H, Christensen NJ. Diuretic treatment in decompensated cirrhosis and congestive heart failure: effect of posture. Br Med J 1986;292:1351-3.
46. Conn HO. Bath is a bath is a bath. Hepatology 1986;6:756-7.
47. Strauss E, De Sa MF, Lacet CM, Crapattida da Silva E, Dos Santos RW. Padronizaçao de conduta terapeutica das ascites do hepatopata cronico. Estudio prospectivo de 100 casos. Gastroenterol Endosc Digest 1985;4:79-86.
48. Gatta A, Angeli P, Caregaro L, Menon F, Sacerdoti D, Merkel C. A pathophysiological interpretation of unresponsiveness to spironolactone in a stepped care approach to the diuretic treatment of ascites in nonazotemic cirrhotic patients. Hepatology 1991;14:231-6.
49. Bernardi M, Laffi G, Salvagnini M, Azzena G, Bonato S. Marra F, et al. Efficacy and safety of the stepped care medical treatment of ascites in liver cirrhosis: a randomised controlled trial comparing two diets with different sodium content. Liver 1993;13:156-62.
50. Gentilini P, Casini-Raggi V, Di Fiore G, Romanelli RG, Buzzelli G, Pinzani M, et al. Albumin improves the response to diuretics in patients with cirrhosis and ascites: results of a randomized, controlled trial. J Hepatol 1999;30:639-45.
51. Santos J, Planas R, Pardo A, Durandez R, Cabré E, Morillas RM, et al. Spironolactone alone or in combination with furosemide in the treatment of moderate ascites in nonazotemic cirrhosis. A randomized comparative study of efficacy and safety. J Hepatol 2003;39:187-92.
52. Reynolds TB, Lieberman FL, Godman AR. Advantages of treatment of ascites without sodium restriction and without complete removal of excess fluid. Gut 1978;19:549-53.
53. Gauthier A, Lévy VG, Quinton A, Michel H, Rueff B, Descos L, et al. Salt or no salt in the treatment of cirrhotic ascites: a randomised study. Gut 1986;27:705-9.
54. Descos L, Gauthier A, Lévy VG, Michel H, Quinton A, Rueff B, et al. Comparison of six treatments of ascites in patients with liver cirrhosis. A clinical trial. Hepatogastroenterology 1983;30:15-20.
55. Ginès P, Berl T, Bernardi M, Bichet DG, Hamon G, Jimenez W, et al. Hyponatremia in cirrhosis: from pathogenesis to treatment. Hepatology 1988;28:851-64.
56. Arroyo V, Claria J, Salo J, Jiménez W. Antidiuretic hormone and pathogenesis of water retention in cirrhosis with ascites. Semin Liver Dis 1994;14:44-58.
57. Pockros PJ, Reynolds TB. Rapid diuresis in patients with ascites from chronic liver disease: the importance of peripheral edema. Gastroenterology 1986;90:1827-33.
58. Shear L, Ching S, Gabuzda GJ. Compartimentalization of ascites and edema in patients with hepatic cirrhosis. N Engl J Med 1970;282:1391-6.
59. Takaya A, Fukui H, Matsumura M, Uemura M, Kojima H, Okamato O, et al. Stepped care medical treatment for cirrhotic ascites: analysis of factors influencing the response to treatment. J Gastroenterol Hepatol 1995;10:30-5.
60. Angeli P, Gatta A, Carregaro L, Menon F, Sacerdoti D, Merkel C, et al. Tubular rate of renal sodium retention in ascitic liver cirrhosis evaluated by lithium clearance. Eur J Clin Invest 1990;20:111-7.
61. Perez-Ayuso RM, Arroyo V, Planas R, Gaya J, Bory F, Rimola A, et al. Randomized comparative study of the efficacy of furosemide versus spironolactone in non azotemic cirrhosis with ascites. Relationship between the diuretic response and the activity of the rennin-aldosterone system. Gastroenterology 1983:84:961-8.
62. Bernardi M, Servadei D, Trevisani F, Rusticali AG, Gasbarrini G. Importance of plasma aldosterone concentration on the natriuretic effect of spironolactone in patients with liver cirrhosis and ascites. Digestion 1985;31:189-93.
63. Katsuta Y, Aramaki T, Sekiyama T, Satomura K, Okumura H, Okumura K. Plasma volume contraction in portal hypertension. J Hepatol 1993;17:S19-23.
64. Aagaard NK, Andersen H, Vilstrup H, Clausen T, Jacobsen J, Dorup N. Muscle strengh, Na, K-pumps, magnesium and potassium in patients with alcoholic liver cirrhosis: relation to spironolactone. J Intern Med 2002;252:56-63.
65. Doggrrell SA, Brown L. The spironolactone renaissance. Expert Opin Investig Drugs 2001;10:943-54.
66. Gabow PA, Moore S, Schrier RW. Spironolactone-induced hyperchloremic acidosis in cirrhosis. Ann Intern Med 1979;90:338-40.
67. Clee MD, Burrow L. Taste and smell in disease. N Engl J Med 1983;309:1062.
68. Andriulli A, Arrigoni A, Gindro T, Karbowiak I, Buzzetti G, Armanini D. Canrenone and androgen receptor-active materials in plasma of cirrhotic patients during long term K-canrenoate or spironolactone therapy. Digestion 1989;44:155-62.
69. Stierer R, Spoula H, Rosen HR. Breast cancer in the male: a retrospective analysis of 15 cases. Onkologie 1990;13:128-131
70. Angeli P, Dalla Pria M, De Bei E, Albino G, Caregaro L, Merkel C, et al. Randomized clinical study of the efficacy of amiloride and potassium canrenoate in nonazotemic cirrhotic patients with ascites. Hepatology 1994;19:72-9.
71. Denoyel P, Calès P, Grasset D, Huguet-Rigal F, Vinel JP, Pascal JP. Pancytopénie aiguë sous triamtérène chez le cirrhotique éthylique: méconnaissance de la pharmacologie clinique du triamtérène. Gastroenterol Clin Biol 1985;9:746.
72. Fogel MR, Sawhney VK, Neal EA, Miller RG, Knauer CM, Gregory PB. Diuresis in the ascitic patient: a randomized controlled trial of three regimens. J Clin Gastroenterol 1981;3(suppl 1):73-80.
73. Arroyo V, Gines P, Gerbes AL, Dudley F, Gentilini P, Laffi G, et al. Definition and diagnostic criteria of refractory ascites in hepatorenal syndrome and cirrhosis. Hepatology 1996;23:164-76.
74. Spahr L, Villeneuve J, Tran HK, Pomier-Layrargues G. Furosemide-induced natriuresis as a test to identify cirrhotic patients with refractory ascites. Hepatology 2001;33:28-31.
75. Quintero E, Ginés P, Arroyo V, Rimola A, Borry F, Planas R, et al. Paracentesis versus diuretics in the treatment of cirrhotics with tense ascites. Lancet 1985;i:611-2.
76. Ginès P, Arroyo V, Quintero E, Planas R, Borry F, Cabrera J, et al. Comparison between paracentesis and diuretics in the treatment of cirrhotic with tense ascites. Gastroenterology 1987;93:234-41.
77. Hagège H, Ink O, Ducreux M, Pelletier G, Buffet C, Etienne JP. Traitement de l'ascite chez les malades atteints de cirrhose sans hyponatrémie ni insuffisance rénale. Résultats d'une étude randomisée comparant les diurétiques et les ponctions compensées par l'albumine. Gastroenterol Clin Biol 1992;16:751-5.
78. Sola R, Vila MC, Andreu M, Oliver MI, Coll S, Gana J, et al. Total paracentesis with dextran-40 vs diuretics in the treatment of ascites with cirrhosis : a randomised controlled study. J Hepatol 1994;20:282-8.
79. Salerno F, Baldalamenti S, Incerti P, Tempinis S, Restilli B, Bruno S, et al. Repeated paracentesis and i.v. albumin infusion to treat « tense » ascites in cirrhotic patients: a safe alternative therapy. J Hepatol 1987;5:102-8.
80. Ginès P, Tito L, Arroyo V, Planas R, Panés J, Viver J, et al. Randomized comparative study of therapeutic paracentesis with and without intravenous albumin in cirrhosis. Gastroenterology 1988;94:1493-502.
81. Wang SS, Lu CW, Chao Y, Lee FY, Chen TW, Lin HC, et al. Total paracentesis in non alcoholic cirrhotic with massive ascites: mid-term effects on systemic and hepatic hemodynamics and renal function. J Gastroenterol 1994;9:592-6.
82. Ginès A, Fernadez-Esparrach G, Monescillo A, Vila C, Doménech E, Abecasis R, et al. Randomized trial comparing albumin, dextran 70, and polygeline in cirrhotic patients with ascites tretated by paracentesis. Gastroenterology 1996;111:1002-10.
83. Pozzi M, Osculati G, Boari G, Serboli P, Colombo P, Lambrughi C, et al. Time course of circulatory and humoral effects of rapid total paracentesis in cirrhotic patients with tense, refractory ascites. Gastroenterology 1994;106:709-19.
84. Tito L, Ginès P, Arroyo V, Planas R, Panés J, Rimola A, et al. Total paracentesis associated with intravenous albumin management of patients with cirrhosis and ascites. Gastroenterology 1990;98:146-51.
85. Planas R, Ginès P, Arroyo V, Llach J, Panes J, Vargas V, et al. Dextran-70 versus albumin as plasma expanders in cirrhotic patients with ascites treated with total paracentesis. Results of a randomised study. Gastroenterology 1990;99:1736-44.
86. Salerno F, Baldalamenti S, Lorenzano E, Moser P, Incerti P. Randomized comparative study of hemacel versus albumin infusion after total paracentesis in cirrhotic patients with refractory ascites. Hepatology 1991;13:707-13.
87. Fassio E, Terg R, Landeira G, Abecasis R, Salemne M, Podesta A, et al. Paracentesis with dextran-70 vs paracentesis with albumin in cirrhosis with tense ascites. Results of a randomised study. J Hepatol 1992;14:310-6.
88. Altman C, Bernard B, Roulot D, Vitte RL, Ink O. Randomized comparative multicenter study of hydroxyethyl starch versus albumin as a plasma expander in cirrhotic patients with tense ascites treated with paracentesis. Eur J Gastroenterol Hepatol 1998;10:5-10.
89. Sola-Vera J, Mirana J, Ricart E, Planella M, Gonzalez B, Torras X, et al. Randomized trial comparing albumin and saline in the prevention of paracentesis-induced circulatory dysfunction in cirrhotic patients with ascites. Hepatology 2003;37:1147-53.
90. Christidis C, Mal F, Ramos J, Senejoux A, Callard P, Navarro R, et al. Worsening of hepatic dysfunction as a consequence of repeated hydroxyethylstarch infusions. J Hepatol 2001;35:726.
91. Fernandez-Esparrach G, Guevara M, Sort P, Pardo A, Jimenez W, Gines P, et al. Diuretic requirements after total paracentesis in non-azotemic patients with cirrhosis. A randomized double-blind trial of spironolactone versus placebo. J Hepatol 1997;26:614-20.
92. Runyon BA. Paracentesis of ascitic fluid: a safe procedure. Arch Intern Med 1986;146:2259-61.
93. Dumortier J, Poncet G, Belbouab S, Pilleul F, Beziat C, Delafosse B, et al. Hémorragie sévère par plaie de l'artère épigastrique après ponction d'ascite. Gastroenterol Clin Biol 2002;26:180-1.
94. Moreau R, Asselah T, Condat B, de Kerguenec C, Pessione F, Bernard B, Poynard T, et al. Comparison of the effect of terlipressin and albumin on arterial blood volume in patients with cirrhosis and tense ascites treated by paracentesis: a randomised study. Gut 2002;50:90-4.
95. Belghiti J, Durand F. Abdominal wall hernies in the setting of cirrhosis. Seminars Liver Dis 1997;3:219-26.
96. Arroyo V, Ginés P, Planas R, Rodés J. Pathogénie, diagnostic et traitement de l'ascite dans la cirrhose. In: Hépatologie clinique. Benhamou JP, Bircher J, McIntyre N, Rizzetto M, Rodès J, éditeurs. Flammarion Médecine-Sciences, Paris 2002, pp 697-731.
97. Rector WG. Spontaneous chylous ascites of cirrhosis. J Clin Gastroenterol 1984;6:369-72.
98. Sultan S, Pauwels A, Poupon R, Lévy VG. Ascite chyleuse du cirrhotique. Une étude rétrospective de 20 cas. Gastroenterol Clin Biol 1990;14:842-7.